An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature

Journal of Pharmaceutical Sciences

Volumn 99, Issue 1, 2010, Pages 196-208

  Sheng, Qi ^a   Weuts, Ilse ^b   De Cort, Steve ^b   Stokbroekx, Sigrid ^b   Leemans, Ruud ^b   Reading, Mike ^a   Belton, Peter ^a   Craig, Duncan Q M ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Amorphous; Cryomilling; Crystallisation; DSC; Etravirine; FTIR; Glass transition; Water sorption

Indexed keywords

ETRAVIRINE;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; DRUG STRUCTURE; GLASS TRANSITION TEMPERATURE; HEATING; HUMIDITY; INFRARED SPECTROSCOPY;

EID: 73949154387     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21811     Document Type: Article

References (29)

1. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. 2001. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliver Rev 48:91-114.
2. Crowley KJ, Zografi G. 2002. Cryogenic grinding of indomethacin polymorphs and solvates: Assessment of amorphous phase formation and amorphous phase physical stability. J Pharm Sci 91:492-507.
3. Chieng N, Zujovic Z, Bowmaker G, Rades T, Saville D. 2006. Effect of milling conditions on the solid-state conversion of ranitidine hydrochloride form I. Int J Pharm 327:36-44.
4. Chung KH, He JH, Shin DH, Schoenung JM. 2003. Mechanisms of microstructure evolution during cryomilling in the presence of hard particles. Mater Sci Eng 356:23-31.
5. Lee L, Zhou F, Chung KH, Kim NJ, Lavernia EJ. 2001. Grain growth of nanocrystalline Ni powders prepared by cryomilling. Metall Mater Trans A 32:3109-3115.
6. 4C reinforced Al nanocomposite. Part I. Effects of process conditions on structure. Metall Mater Trans A 37:3099-3109 (2006).
7. Chamarthy SP, Pinal R. 2008. The nature of crystal disorder in milled pharmaceutical materials. Colloid Surf A-Physicochem Eng Asp 331:68-75.
8. Feng T, Pinal R, Carvajal MT. 2008. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of Griseofulvin. J Pharm Sci 97:3207-3221.
9. Witkin DB, Lavernia EJ. 2006. Synthesis and mechanical behaviour of nanostructured materials via cryomilling. Prog Mater Sci 51:1-60.
10. Zhang GG, Gu C, Zell MT, Burkhardt RT, Munson EJ, Grant DJ. 2002. Crystallization and transitions of sulfamerazine polymorphs. J Pharm Sci 91:1089-1100.
11. Okamoto PR, Lam NQ, Rehn LE. 1999. Physics of crystal-to- glasstransformations. In: Ehrenreich H, Spaepen F, editors. Solid state physics. New York: Academic Press. pp. 1-135.
12. Fecht HJ. 1992. Defect-induced melting and solid-state amorphisation. Nature 356:133-135.
13. Descamps M, Willart JF, Dudognon E, Caron V. 2007. Transformation of pharmaceutical compounds upon milling and comilling: The role of Tg. J Pharm Sci 96:1398-1407.
14. Willart JF, Caron V, Lefort R, Danede F, Prevost D, Descamps M. 2004. A thermal character of the solid state amorphization of lactose induced by ball milling. Solid State Commun 132:693-696.
15. Willart JF, Descamps N, Caron V, Capet V, Danede F, Descamps M. 2006. Formation of lactose-mannitol molecular alloys by solid state vitrification. Solid State Commun 138:194-199.
16. Martin G, Bellon P. 1997. Driven alloys. Solid State Phys 50:189-331.
17. Yoshioka M, Hancock BC, Zografi G. 1994. Crystallization of indomethacin from the amorphous state below and above the glass transition temperature. J Pharm Sci 83:1700-1705.
18. Jones KJ, Kinshott I, Reading M, Lacey AA, Nikolopoulos C, Pollock HM. 1997. The origin and interpretation of the signals of MTDSC. Thermochim Acta 304-305:187-199.
19. Verdonck E, Schaap K, Thomas LC. 1999. A discussion of the principles and applications of modulated temperature DSC (MTDSC). Int J Pharm 192:3-20.
20. Saklatvala R, Royall PG, Craig DQM. 1999. The detection of amorphous material in a nominally crystalline drug using modulated temperature DSC - A case study. Int J Pharm 192:55-62.
21. McPhillips H, Craig DQM, Royall PG, Hill VL. 1999. Characterisation of the glass transition of HPMC using modulated temperature differential scanning calorimetry. Int J Pharm 180:83-90.
22. Helmy R, Zhou GX, Chen WY, Crocker L, Wang T, Wenslow RM, Vailaya A. 2003. Characterization and quantitation of aprepitant drug substance polymorphs by attenuated total reflectance Fourier transform infrared spectroscopy. Anal Chem 75:605-611.
23. Avrami M. 1939. Kinetics of phase change. I. General theory. J Chem Phys 7:1103-1112.
24. Avrami M. 1940. Kinetics of phase change. II. Transformation-time relations for random distribution of nuclei. J Chem Phys 8:212-224.
25. Avrami M. 1941. Kinetics of phase change. III. Granulation, phase change, and microstructure. J Chem Phys 9:177-184.
26. Christian JW. 1975. The theory of transformation in metals and alloys. 2nd edition. New York: Pergammon.
27. Sha W. 2005. Computer modelling of isothermal crystallisation kinetics of electroless and melt quenched amorphous solids using Johnson-Mehl-Avrami theory. Mater Sci Technol 21:69-75.
28. Frade JR. 1993. Kinetics of nucleation and growth. J Mater Sci 28:6715-6718.
29. Abu-Sehly AA, Elabbar AA. 2007. Kinetics of crystallization in amorphous Se73.2Te21.1Sb5.7 under isochronal conditions: Effect of heating rate on the activation energy. Physica B 390:196-202.